已收盘 12-12 16:00:00 美东时间
+0.030
+1.09%
Guggenheim analyst Brad Canino downgrades Black Diamond Therapeutic (NASDAQ:BDTX) from Buy to Neutral.
12-04 21:48
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to present results
12-03 05:02
今日重点评级关注:Oppenheimer:维持Olema Pharmaceuticals"跑赢大市"评级,目标价从22美元升至45美元;Bernstein:维持Atlassian"跑赢大市"评级,目标价从290美元升至304美元
11-19 11:01
Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.23) by 35.9 percent. This is a 46.43 percent increase over losses of $(0.28) per
11-06 20:35
Black Diamond Therapeutics reported financial results for Q3 2025, highlighting $135.5 million in cash, sufficient for operations into Q4 2027. The company plans to disclose ORR and preliminary duration data for silevertinib in 1L EGFRm NSCLC later this quarter. R&D expenses decreased to $7.4 million, and net loss was $8.5 million. Black Diamond is seeking partnerships and FDA feedback for silevertinib's development.
11-06 12:30
Clarus Corporation announced a quarterly cash dividend of $0.025 per share, payable on November 26, 2025, to stockholders of record as of November 17, 2025. Headquartered in Salt Lake City, Utah, Clarus is a global leader in outdoor equipment and lifestyle products, with brands including Black Diamond®, Rhino-Rack®, MAXTRAX®, TRED Outdoors®, and RockyMounts®.
11-05 21:15
今日重点评级关注:Rosenblatt:维持HIVE Digital Technologies"买入"评级,目标价从5美元升至10美元;摩根大通:维持Array Technologies"超配"评级,目标价从13美元升至15美元
10-17 09:58
Stifel analyst Laura Prendergast reinstates Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and announces $8 price target.
10-16 21:50
来源:IT桔子 IT桔子出品 投资 13 October 星期一 每日风险投资速递 TIPS: 1、下载 IT桔子 APP,实时跟...
10-14 15:02